This identification was published in 1973 and represents the foundational paper of the GHK research literature
Tirzepatide, a dual GIP/GLP-1 agonist, shows numerically higher response rates in trialsapproximately 85% achieve 5% or greater weight losspartly because it targets two appetite pathways instead of one
6.2 Systemic metabolism: conjugation and deconjugation Dietary polyphenols and microbial metabolites of procyanidins typically undergo a phase II metabolism in enterocytes and liver cells to form glucuronic acid, sulfate, and methyl conjugates (Figure 3) (27, 41, 73, 82, 83)
Rather than stopping tirzepatide completely, many patients benefit from continuing at a lower maintenance dose or switching to a lower-cost alternative like compounded semaglutide, which activates GLP-1 alone and may cost less while still providing meaningful appetite control
This will also take into consideration whether youve had side effects or not
The researchers reported higher VEGFR2 mRNA and protein expression after BPC-157 exposure
